Table 3 Efficacy results of randomized studies evaluating bevacizumab plus chemotherapy in patients with mCRC in first-line treatment

 Hurwitz 2004/2005 [14, 42] (AVF 2107)

402

IFL/Bev

44.8 %

10.6 months

20.3 months

411

IFL/placebo

34.8 %

6.2 months

15.6 months

p = 0.004

HR: 0.54 (0.37–0.78)

HR: 0.66 (0.52–0.85)

 Guan 2011 [24] (ARTIST)

139

IFL/Bev

35.3 %

8.3 months

18.7 months

64

IFL

17.2 %

4.2 months

13.4 months

p = 0.013

HR: 0.44 (0.31–0.63)

HR: 0.62 (0.41–0.95)

 Stathopoulos 2010 [44]

114

IFL/Bev

36.8 %

NR

22 months

108

IFL

35.2 %

25 months

p = NS

HR: 1.05 (0.81–1.36)^b

 Saltz/Cassidy 2008/2011 [45, 46] (NO16966)

699

XELOX or FOLFOX/Bev

47 %

9.4 months

21.3 months

701

XELOX or FOLFOX/placebo

49 %

8.0 months

19.9 months

p = 0.31

HR: 0.83 (0.72–0.95)^a

HR: 0.89 (0.76–1.03)

 Passardi 2013/2015 [21, 23] (ITACA)^c

176

FOLFOX or FOLFIRI/Bev

50.6 %

9.6 months

20.8 months

194

FOLFOX or FOLFIRI

50 %

8.4 months

21.3 months

p = 0.865

HR: 0.86 (0.70-1.07)

HR: 1.13 (0.89-1.43)

 Kabinnavar 2003 [47] (AVF0780)

35

5-FU/LV/Bev (5 mg/kg)

40 %

9.0 months

21.5 months

33

5-FU/LV/Bev (10 mg/kg)

24 %

7.2 months

16.1 months

36

5-FU/LV

17 %

5.2 months

13.8 months

(p = 0.08)

HR: 0.54 (0.33–0.88)

HR: NR

 Kabinnavar 2005 [48] (AVF2192)

104

5-FU/LV/Bev

26 %

9.2 months

16.6 months

105

5-FU/LV

15.2 %

5.5 months

12.9 months

p = 0.055

HR: 0.50 (0.35–0.73)

HR: 0.79 (0.56–1.10)

 Tebutt 2010 [40] (MAX)

157

Capecitabine/Bev

38.1 %

8.5 months

NR

156

Capecitabine

30.3 %

5.7 months

p = 0.16

HR: 0.63 (0.50–0.79)

HR: 0.88 (0.68–1.13)

 Cunningham 2013 [22] (AVEX)

140

Capecitabine/Bev

19 %

9.1 months

20.7 months

140

Capecitabine

10 %

5.1 months

16.8 months

p = 0.04

HR: 0.53 (0.41–0.69)

HR: 0.79 (0.57–1.09)